Technical Analysis for FENC - Fennec Pharmaceuticals Inc.

Grade Last Price % Change Price Change
C 11.12 0.32% 0.04
FENC closed up 0.32 percent on Thursday, March 28, 2024, on approximately normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
Earnings Movers Other 0.00%
Boomer Buy Setup Bullish Swing Setup 0.32%
Spinning Top Other 0.32%
NR7 Range Contraction 0.32%
NR7-2 Range Contraction 0.32%
Narrow Range Bar Range Contraction 0.32%
Gapped Up Strength 0.32%
Boomer Buy Setup Bullish Swing Setup 2.11%
Calm After Storm Range Contraction 2.11%
NR7 Range Contraction 2.11%

   Recent Intraday Alerts

Alert Time
Boomer Buy Entry about 21 hours ago
Rose Above Previous Day's High about 21 hours ago
Up 2% about 21 hours ago
Up 1% about 21 hours ago
Possible NR7 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Fennec Pharmaceuticals Inc. Description

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Oncology Blastoma Hearing Sarcoma Brain Tumor Cancer Therapeutics Childhood Neuroblastoma Neoplasms Hearing Loss Localized Tumors Osteosarcoma

Is FENC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.92
52 Week Low 6.3
Average Volume 117,475
200-Day Moving Average 8.84
50-Day Moving Average 9.95
20-Day Moving Average 10.32
10-Day Moving Average 10.91
Average True Range 0.47
RSI (14) 67.21
ADX 35.8
+DI 26.99
-DI 6.96
Chandelier Exit (Long, 3 ATRs) 10.09
Chandelier Exit (Short, 3 ATRs) 10.66
Upper Bollinger Bands 11.60
Lower Bollinger Band 9.03
Percent B (%b) 0.81
BandWidth 24.89
MACD Line 0.39
MACD Signal Line 0.30
MACD Histogram 0.0897
Fundamentals Value
Market Cap 297.01 Million
Num Shares 26.7 Million
EPS -0.75
Price-to-Earnings (P/E) Ratio -14.83
Price-to-Sales 20.81
Price-to-Book 84.82
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.62
Resistance 3 (R3) 11.64 11.51 11.53
Resistance 2 (R2) 11.51 11.38 11.49 11.50
Resistance 1 (R1) 11.31 11.30 11.25 11.29 11.48
Pivot Point 11.18 11.18 11.14 11.16 11.18
Support 1 (S1) 10.98 11.05 10.92 10.96 10.76
Support 2 (S2) 10.85 10.97 10.83 10.74
Support 3 (S3) 10.65 10.85 10.71
Support 4 (S4) 10.63